Research digest / doses studied
Sermorelin dosage, as the studies recorded it.
The doses, routes, and durations used in published research — reported in "studied at X in [population]" form, never as a recommendation.
Before the details
This page reports the sermorelin dosage figures that appear in published studies — what was given, to whom, by which route, for how long. It is a record, not a protocol: research-grade sermorelin is supplied for laboratory work, not as a medicine to self-administer, so there are no instructions here for a person to follow. Doses in studies were set per body weight (for example, micrograms per kilogram) or as fixed milligram amounts, almost always by subcutaneous (under-the-skin) injection. Read the numbers as data points from the literature, each tied to the study that used them.
Doses Used in Sermorelin Research
The pediatric efficacy work used 30 mcg/kg/day subcutaneously at bedtime in growth-hormone-deficient children, the regimen that raised first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. Aging research in older men used 0.5 mg and 1 mg subcutaneously twice daily for 14 days, where the higher dose restored GH and IGF-1 toward young-adult levels [2]. A long-term analog study had age-advanced men and women self-inject 10 mcg/kg nightly for 16 weeks [9].
Pharmacokinetic and diagnostic work used the intravenous route: in 30 healthy men, intravenous GHRH(1-29)NH2 elicited GH release at doses as low as 0.25 mcg/kg, with maximal release around 1-2 mcg/kg [3]. Historically, a single intravenous bolus (commonly about 1 mcg/kg) was used to test pituitary GH reserve. These are the figures the studies report; none is offered as guidance for use in a person.
The diagnostic dose, historically
Beyond therapy, GHRH(1-29) had a diagnostic life. A single intravenous bolus — commonly around 1 mcg/kg — was used historically as a GH stimulation test: give the secretagogue, then measure how much GH the pituitary can release, as a read on its reserve. The pharmacokinetic study that mapped the dose-response supports the logic, showing significant GH release from doses as low as 0.25 mcg/kg and a maximal response near 1-2 mcg/kg in healthy men [3]. This is a one-time provocative dose for measurement, not a treatment regimen, and it is included here only to show the full range of doses the literature recorded — diagnostic, pediatric-therapeutic, and adult-research — each tied to a different purpose.
Routes studied
Subcutaneous injection is the primary route across the efficacy and aging studies [1][2][9]. Intravenous dosing appears in the pharmacokinetic and diagnostic literature [3]. The intranasal route was tested historically but performed poorly — bioavailability was only about 3-5%, meaning the overwhelming majority of an intranasal dose never reached circulation [3]. That low mucosal absorption is the practical reason GHRH(1-29) was studied as an injection, and it tracks with the wider criticism that oral, sublingual, and troche "sermorelin" products are degraded before they can act.
Reconstitution and stability context
Sermorelin acetate is supplied as a lyophilized powder and reconstituted with sterile diluent; once in solution it is typically refrigerated, because aqueous peptide solutions are prone to degradation [3]. Compounded preparations are made under USP sterile-compounding standards. This is handling and stability context from the literature and compounding framework — it describes how the material behaves, not how anyone should dose it.
Why these figures are written as "studied at X in [population]"
Every dose on this page is framed the same way on purpose: a quantity, a route, and the population it was tested in — never "the recommended dose." That convention is not legal throat-clearing; it is the most accurate way to report what the studies contain. A figure like 30 mcg/kg/day means something in GH-deficient children with a height-velocity endpoint [1] and something quite different transplanted onto a healthy adult, where no equivalent controlled outcome exists. The same is true of the 0.5-1 mg twice-daily figure from a 14-day older-men study [2] and the 10 mcg/kg nightly figure from a 16-week analog study [9]. Reporting the population alongside the number is what keeps a dose a data point rather than an instruction — and it is why nothing here should be read as guidance for use in a person.
The populations the doses were tested in
Dose figures only mean something attached to who received them. The 30 mcg/kg/day regimen was studied in prepubertal growth-hormone-deficient children — a population with a defined deficiency and a clear endpoint (height velocity) [1]. The 0.5-1 mg twice-daily regimen was studied in healthy older men with age-related GH decline, over just 14 days [2]. The 10 mcg/kg nightly regimen was studied in age-advanced men and women across 16 weeks [9]. The intravenous microgram-per-kilogram doses came from pharmacokinetic and diagnostic studies in healthy adults [3]. None of these populations is "a healthy adult seeking anti-aging benefit," which is exactly the gap between the dosing literature and the way the compound is marketed — and why the body-composition page keeps the credible numbers tied to tesamorelin rather than borrowed for sermorelin [6].
Why dosing schedules varied
Study durations ranged from 14 days in older men [2] to 16 weeks in the analog study [9] to a 20-week GHRH-analog cognition trial [6] to 12-24 months in pediatric work [1]. Because each study set its own dose, route, and timeline to answer its own question, the literature does not define a single fixed course. The practical takeaway is interpretive: outcomes were measured per study, and reading any one regimen as a general rule overreads the data.